Biocon Opens First U.S. Manufacturing Facility in Cranbury, New Jersey
CRANBURY, New Jersey, September 11, 2025 — Biocon Limited has inaugurated its first U.S. manufacturing facility in Cranbury, New...
Oncology
Advertisement
Glenmark Launches Phase 3 Global Study of Envafolimab for Lung Cancer
MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...
Tagworks Advances TGW101 in Phase 1 Trial for Solid Tumors
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
FDA Adds Modeyso (dordaviprone) to Oncology Guidelines for H3 K27M-Mutant Diffuse Glioma
September 9, 2025 – In a significant advancement for neuro-oncology, Modeyso (dordaviprone) has been included in the National Oncology...
Atossa Pursues FDA Path for Low-Dose (Z)-Endoxifen in Breast Cancer Prevention
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
Advertisements
IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
FDA Grants Breakthrough Therapy Designation to HERNEXEOS® for First-Line Treatment of HER2-Mutant Advanced NSCLC
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
Advertisement
